These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Case study: working safely with beryllium oxide. Berakis M Occup Health Saf; 2009 May; 78(5):34, 36, 38 passim. PubMed ID: 19480368 [TBL] [Abstract][Full Text] [Related]
24. RE: Anything but beryllium: The beryllium industry's corruption of safety information. Kolanz ME Am J Ind Med; 2003 May; 43(5):553-4. PubMed ID: 12704629 [No Abstract] [Full Text] [Related]
25. [Beryllium--underestimated occupational health hazard in Poland]. Dudek W; Walusiak J; Wittczak T Med Pr; 2001; 52(6):471-8. PubMed ID: 11928678 [TBL] [Abstract][Full Text] [Related]
26. How a state health agency prevents occupational disease. Lieben J; Hill PC Ind Med Surg; 1966 Jun; 35(6):489-94. PubMed ID: 5220623 [No Abstract] [Full Text] [Related]
28. Skin granulomata due to beryllium oxide. Williams WJ; Lawrie JH; Davies HJ Br J Surg; 1967 Apr; 54(4):292-7. PubMed ID: 6021765 [No Abstract] [Full Text] [Related]
29. Keeping beryllium workers safe: an enhanced preventive model. Deubner D; Kent M J Occup Environ Hyg; 2007 Mar; 4(3):D23-30. PubMed ID: 17237019 [No Abstract] [Full Text] [Related]
30. Comment on corporate strategy: beryllium, Brush Wellman, and NIOSH. Rodrigues E New Solut; 2007; 17(4):283-4. PubMed ID: 18184620 [No Abstract] [Full Text] [Related]
31. [Genotoxic effects caused in workers by beryllium compounds]. Gazalieva MA Med Tr Prom Ekol; 2009; (9):32-6. PubMed ID: 19877441 [TBL] [Abstract][Full Text] [Related]
32. Adjustment for temporal confounders in a reanalysis of a case-control study of beryllium and lung cancer. Schubauer-Berigan MK; Deddens JA; Steenland K; Sanderson WT; Petersen MR Occup Environ Med; 2008 Jun; 65(6):379-83. PubMed ID: 17890301 [TBL] [Abstract][Full Text] [Related]
33. Rejoinder: Progress in understanding the relationship between beryllium exposure and lung cancer. Deubner DC; Roth HD Epidemiology; 2009 May; 20(3):341-3. PubMed ID: 19295436 [No Abstract] [Full Text] [Related]
34. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Kreiss K; Mroz MM; Newman LS; Martyny J; Zhen B Am J Ind Med; 1996 Jul; 30(1):16-25. PubMed ID: 8837677 [TBL] [Abstract][Full Text] [Related]
36. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Fontenot AP; Maier LA Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719 [TBL] [Abstract][Full Text] [Related]
37. Review of control problems in operations using various beryllium compounds. VILES FJ AMA Arch Ind Health; 1959 Feb; 19(2):239-53. PubMed ID: 13616750 [No Abstract] [Full Text] [Related]
38. Problems in the safe operation of certain beryllium-using processes. EPSTEIN A AMA Arch Ind Health; 1959 Feb; 19(2):225-30. PubMed ID: 13616748 [No Abstract] [Full Text] [Related]
39. Medical control of beryllium; discussion of paper by Dr. Zielinski. HARDY HL AMA Arch Ind Health; 1959 Feb; 19(2):203-4. PubMed ID: 13616744 [No Abstract] [Full Text] [Related]
40. Beryllium: hazard evaluation and control in research and development operations. HYATT EC; SCHULTE HF; MTTCHELL RN; TANGMAN EP AMA Arch Ind Health; 1959 Feb; 19(2):211-20. PubMed ID: 13616746 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]